Neurological or ocular tumour or cancer: Individual from a family in whom a mutation in a cancer predisposition gene has NOT been identified
ADULT
PAEDIATRIC
-
Emergency
If any of the following are present or suspected, please refer the patient to the emergency department (via ambulance if necessary) or follow local emergency care protocols or seek emergent medical advice if in a remote region.
- No referrals to emergency relating to clinical genetics
-
Other useful information for referring practitioners Not and exhaustive list
Minimum Referral Criteria
-
Category 1
(appointment within 30 calendar days)- A personal history of a brain tumour with a family history of brain tumours and/or other Li-Fraumeni associated cancers
- Metastatic uveal melanoma in a patient fulfilling Cat 2 criteria
- BAP1 deficient meningioma
-
Category 2
(appointment within 90 calendar days)- An individual whose referral to GHQ was recommended after review of a relative.
- Non-metastatic uveal melanoma in a patient with a personal or family history of BAPomas, renal cancer, mesothelioma or meningioma
- CHRPE (Congenital retinal pigment epithelial hypertrophy)
-
Category 3
(appointment within 365 calendar days)- Retinoblastoma (See Paediatric cancer)
- Uveal melanoma fulfilling Cat 2 criteria and diagnosed ≥3 years ago
- Central or peripheral nervous system conditions which may be suggestive of familial cancer predisposition condition including:
- endolymphatic sac tumour
- ciliary body medulloepithelioma
- pituitary blastoma or pineoblastoma
- retinal angioma diagnosed at age < 40 years
- CNS haemangioblastoma diagnosed at age < 30yrs
- two or more retinal angiomas or CNS haemangioblastomas at any age
- unilateral vestibular schwannoma diagnosed at age < 30 years
- cranial meningioma diagnosed at age < 20 years
- multiple meningiomas or meningioma and two or more blood relatives with meningioma
- schwannoma diagnosed at age < 16 years
- optic nerve pathway, brain or spinal cord glioma in a patient with a personal or family history suggestive of NF1
- typical NF2 related retinal hamartoma diagnosed at age < 16 years
- two NF2-related tumours at any age e.g. meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities
- an individual with two or more CNS cavernomas (cerebral cavernous malformations) or one CNS cavernoma and a family history of CNS cavernomas (also see Neurology genetics condition within Genetics CPC)
Please insert the below information and minimum referral criteria into referral
1. Reason for request Indicate on the referral
2. Essential referral information Referral will be returned without this
- As much detail as possible about the patient's personal history of cancer including the following:
- type/s of cancer
- age at diagnosis
- treatment including outcome
- known relevant family history
- Confirmation of OOHC (where appropriate) and contact details to send correspondence for OOHC
- Relevant pathology including results of any genetic testing if performed (if results are available on Auslab please indicate this on referral)
- Relevant imaging
3. Additional referral information Useful for processing the referral
- If the family is known to GHQ, include the GHQ reference number (GF) if known
- If the patient is being referred for CHRPE, a description of the type or photo from the optometrist/ophthalmologist
4. Request
-
General referral information
Patient's Demographic Details
- Full name (including aliases)
- Date of birth
- Residential and postal address
- Telephone contact number/s – home, mobile and alternative
- Medicare number (where eligible)
- Name of the parent or caregiver (if appropriate)
- Preferred language and interpreter requirements
- Identifies as Aboriginal and/or Torres Strait Islander
Referring Practitioner Details
- Full name
- Full address
- Contact details – telephone, fax, email
- Provider number
- Date of referral
- Signature
Relevant clinical information about the condition
- Presenting symptoms (evolution and duration)
- Physical findings
- Details of previous treatment (including systemic and topical medications prescribed) including the course and outcome of the treatment
- Body mass index (BMI)
- Details of any associated medical conditions which may affect the condition or its treatment (e.g. diabetes), noting these must be stable and controlled prior to referral
- Current medications and dosages
- Drug allergies
- Alcohol, tobacco and other drugs use
Reason for request
- To establish a diagnosis
- For treatment or intervention
- For advice and management
- For specialist to take over management
- Reassurance for GP/second opinion
- For a specified test/investigation the GP can't order, or the patient can't afford or access
- Reassurance for the patient/family
- For other reason (e.g. rapidly accelerating disease progression)
- Clinical judgement indicates a referral for specialist review is necessary
Clinical modifiers
- Impact on employment
- Impact on education
- Impact on home
- Impact on activities of daily living
- Impact on ability to care for others
- Impact on personal frailty or safety
- Identifies as Aboriginal and/or Torres Strait Islander
Other relevant information
- Willingness to have surgery (where surgery is a likely intervention)
- Choice to be treated as a public or private patient
- Compensable status (e.g. DVA, Work Cover, Motor Vehicle Insurance, etc.)
-
Notes
-
Please note that where appropriate and where available, the referral may be streamed to an associated public allied health and/or nursing service. Access to some specific services may include initial assessment and management by associated public allied health and/or nursing, which may either facilitate or negate the need to see the public medical specialist.
-
A change in patient circumstance (such as condition deteriorating, or becoming pregnant) may affect the urgency categorisation and should be communicated as soon as possible.
-
Please indicate in the referral if the patient is unable to access mandatory tests or investigations as they incur a cost or are unavailable locally.
-
Last updated: 13 June 2023
